Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Primerdesign, its molecular diagnostics division, has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Bruker). http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update_Bruker-ENGLISH-25.03.20.pdf
Visit PageYear: 2020
Contract manufacturing services agreement signed with Yourgene Health Plc Additional manufacturing capacity to support demand for Novacyt’s COVID-19 diagnostic test
Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the notification on 20 March 2020, the Company has signed an agreement for certain contract manufacturing services with Yourgene Health Plc (“Yourgene”) (AIM: YGEN), an international molecular diagnostics group.
Visit PageAutorisation d’utilisation d’urgence de la FDA aux Etats-Unis du test pour le COVID-19 Approbation en Indonésie du test COVID-19 RUO
Paris, France et Camberley, Royaume-Uni – 23 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer que la Food and Drug Administration (FDA) des États-Unis a délivré une autorisation d’utilisation d’urgence (Emergency Use Authorization, EUA) pour son test COVID-19. En conséquence, les hôpitaux et
Visit Page